Ara
Toplam kayıt 2, listelenen: 1-2
The Impact Of Jak1/Jak2 Inhibitor Ruxolitinib On The Spleen Size And Symptom Burden In Myeloproliferative Diseases
(Akad Doktorlar Yayınevi, 2016)
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has ...
The Impact Of Iron Overload On Transplant-Related Complications And Prognosis Of Acute Leukemias
(Akad Doktorlar Yayınevi, 2016)
The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. Unfortunately, some of the ...